Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients and Treatment
2.2. Statistical Analysis
3. Results
3.1. Patient Characteristics According to the LPT
3.2. Overall and Progression-Free Survival According to the LPT
3.3. Response to the Anti-EGFR Therapy in KRAS Wild-Type mCRC Patients
3.4. HER2 Expression
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Nagai, Y.; Kiyomatsu, T.; Gohda, Y.; Otani, K.; Deguchi, K.; Yamada, K. The primary tumor location in colorectal cancer: A focused review on its impact on surgical management. GHM 2021, 3, 386–393. [Google Scholar] [CrossRef]
- Ra, H.; Jeong, S.; Lee, H.; Chung, J.-W.; Kim, K.O.; Lee, W.-S.; Kim, J.; Kwon, K.A.; Kim, J.H. Clinicopathological Differences between Right and Left Colorectal Cancer by Sex. JCM 2024, 13, 2810. [Google Scholar] [CrossRef]
- Ramadan, M.; Alfayea, T.; Alsofyani, A.; Alyabsi, M.; Alhusseini, N.; Algarni, A.S. Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis. Cancer Treat. Res. Commun. 2022, 33, 100632. [Google Scholar] [CrossRef]
- Li, F.; Lai, M. Colorectal cancer, one entity or three. J. Zhejiang Univ. Sci. B 2009, 10, 219–229. [Google Scholar] [CrossRef] [PubMed]
- Tejpar, S.; Stintzing, S.; Ciardiello, F.; Tabernero, J.; Van Cutsem, E.; Beier, F.; Esser, R.; Lenz, H.-J.; Heinemann, V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017, 3, 194–201. [Google Scholar] [CrossRef] [PubMed]
- Loupakis, F.; Yang, D.; Yau, L.; Feng, S.; Cremolini, C.; Zhang, W.; Maus, M.K.H.; Antoniotti, C.; Langer, C.; Scherer, S.J.; et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J. Natl. Cancer Inst. 2015, 107, dju427. [Google Scholar] [CrossRef]
- Arnold, D.; Lueza, B.; Douillard, J.-Y.; Peeters, M.; Lenz, H.-J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J.-P.; Tabernero, J.; et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 2017, 28, 1713–1729. [Google Scholar] [CrossRef]
- Weiss, J.M.; Pfau, P.R.; O’Connor, E.S.; King, J.; LoConte, N.; Kennedy, G.; Smith, M.A. Mortality by Stage for Right- Versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare Data. JCO 2011, 29, 4401–4409. [Google Scholar] [CrossRef] [PubMed]
- Mirón Fernández, I.; Mera Velasco, S.; Turiño Luque, J.D.; González Poveda, I.; Ruiz López, M.; Santoyo Santoyo, J. Right and Left Colorectal Cancer: Differences in Post-Surgical-Care Outcomes and Survival in Elderly Patients. Cancers 2021, 13, 2647. [Google Scholar] [CrossRef]
- Huyghe, J.R.; Harrison, T.A.; Bien, S.A.; Hampel, H.; Figueiredo, J.C.; Schmit, S.L.; Conti, D.V.; Chen, S.; Qu, C.; Lin, Y.; et al. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut 2021, 70, 1325–1334. [Google Scholar] [CrossRef] [PubMed]
- Nouri, R.; Hasani, A.; Masnadi Shirazi, K.; Alivand, M.R.; Sepehri, B.; Sotoudeh, S.; Hemmati, F.; Fattahzadeh, A.; Abdinia, B.; Ahangarzadeh Rezaee, M. Mucosa-Associated Escherichia coli in Colorectal Cancer Patients and Control Subjects: Variations in the Prevalence and Attributing Features. Can. J. Infect. Dis. Med. Microbiol. 2021, 2021, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Lei, S.; Ge, Y.; Tian, S.; Cai, B.; Gao, X.; Wang, N.; Wang, G.; Wang, L.; Wang, Z. Colorectal Cancer Metastases to Brain or Bone and the Relationship to Primary Tumor Location: A Population-Based Study. J. Gastrointest. Surg. 2020, 24, 1833–1842. [Google Scholar] [CrossRef] [PubMed]
- Jess, T.; Horváth-Puhó, E.; Fallingborg, J.; Rasmussen, H.H.; Jacobsen, B.A. Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study. Am. J. Gastroenterol. 2013, 108, 1869–1876. [Google Scholar] [CrossRef]
- Araki, K.; Furuya, Y.; Kobayashi, M.; Matsuura, K.; Ogata, T.; Isozaki, H. Comparison of Mucosal Microvasculature between the Proximal and Distal Human Colon. J. Electron. Microsc. 1996, 45, 202–206. [Google Scholar] [CrossRef]
- Kohoutova, D.; Smajs, D.; Moravkova, P.; Cyrany, J.; Moravkova, M.; Forstlova, M.; Cihak, M.; Rejchrt, S.; Bures, J. Escherichia colistrains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect. Dis. 2014, 14, 733. [Google Scholar] [CrossRef] [PubMed]
- Gao, Z.; Guo, B.; Gao, R.; Zhu, Q.; Qin, H. Microbiota disbiosis is associated with colorectal cancer. Front. Microbiol. 2015, 6, 20. [Google Scholar] [CrossRef]
- Missiaglia, E.; Jacobs, B.; D’Ario, G.; Di Narzo, A.F.; Soneson, C.; Budinska, E.; Popovici, V.; Vecchione, L.; Gerster, S.; Yan, P.; et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 2014, 25, 1995–2001. [Google Scholar] [CrossRef]
- Brouwer, N.P.M.; Van Der Kruijssen, D.E.W.; Hugen, N.; De Hingh, I.H.J.T.; Nagtegaal, I.D.; Verhoeven, R.H.A.; Koopman, M.; De Wilt, J.H.W. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. Ann. Surg. Oncol. 2020, 27, 1580–1588. [Google Scholar] [CrossRef]
- Bratei, A.A.; Stefan-van Staden, R.-I. The Importance of KRAS Quantification for a Clinicopathological Characterization in Colorectal Cancer Patients. MEDIN 2023, 1, 20–26. [Google Scholar] [CrossRef]
- Linardou, H.; Briasoulis, E.; Dahabreh, I.J.; Mountzios, G.; Papadimitriou, C.; Papadopoulos, S.; Bafaloukos, D.; Kosmidis, P.; Murray, S. All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat. Rev. 2011, 37, 221–233. [Google Scholar] [CrossRef]
- Davis, A.A.; Cristofanilli, M. Detection of Predictive Biomarkers Using Liquid Biopsies. In Predictive Biomarkers in Oncology; Badve, S., Kumar, G.L., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 107–117. ISBN 978-3-319-95227-7. [Google Scholar]
- Schirripa, M.; Cohen, S.A.; Battaglin, F.; Lenz, H.-J. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin. Oncol. 2018, 45, 124–132. [Google Scholar] [CrossRef] [PubMed]
- Sjoquist, K.M.; Renfro, L.A.; Simes, R.J.; Tebbutt, N.C.; Clarke, S.; Seymour, M.T.; Adams, R.; Maughan, T.S.; Saltz, L.; Goldberg, R.M.; et al. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI J. Natl. Cancer Inst. 2018, 110, 638–648. [Google Scholar] [CrossRef] [PubMed]
- Cheng, X. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes 2024, 15, 903. [Google Scholar] [CrossRef] [PubMed]
- Meric-Bernstam, F.; Hurwitz, H.; Raghav, K.P.S.; McWilliams, R.R.; Fakih, M.; VanderWalde, A.; Swanton, C.; Kurzrock, R.; Burris, H.; Sweeney, C.; et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019, 20, 518–530. [Google Scholar] [CrossRef] [PubMed]
- Iqbal, N.; Iqbal, N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol. Biol. Int. 2014, 2014, 852748. [Google Scholar] [CrossRef]
- Achalla, L.S.V.; Shinde, R.K.; Jogdand, S.; Vodithala, S. Review of the Role of HER2/neu in Colorectal Carcinomas. Cureus 2022, 14, e25409. [Google Scholar] [CrossRef]
- Sartore-Bianchi, A.; Trusolino, L.; Martino, C.; Bencardino, K.; Lonardi, S.; Bergamo, F.; Zagonel, V.; Leone, F.; Depetris, I.; Martinelli, E.; et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016, 17, 738–746. [Google Scholar] [CrossRef]
- Poston, G.J.; Figueras, J.; Giuliante, F.; Nuzzo, G.; Sobrero, A.F.; Gigot, J.-F.; Nordlinger, B.; Adam, R.; Gruenberger, T.; Choti, M.A.; et al. Urgent Need for a New Staging System in Advanced Colorectal Cancer. JCO 2008, 26, 4828–4833. [Google Scholar] [CrossRef]
- National Comprehensive Cancer Network Washington: Clinical Practice Guidelines in Oncology, Inc. Available online: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (accessed on 28 January 2024).
- Siravegna, G.; Mussolin, B.; Buscarino, M.; Corti, G.; Cassingena, A.; Crisafulli, G.; Ponzetti, A.; Cremolini, C.; Amatu, A.; Lauricella, C.; et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 2015, 21, 795–801. [Google Scholar] [CrossRef]
- Lee, G.H.; Malietzis, G.; Askari, A.; Bernardo, D.; Al-Hassi, H.O.; Clark, S.K. Is right-sided colon cancer different to left-sided colorectal cancer?—A systematic review. Eur. J. Surg. Oncol. (EJSO) 2015, 41, 300–308. [Google Scholar] [CrossRef]
- Lee, H.; Sha, D.; Foster, N.R.; Shi, Q.; Alberts, S.R.; Smyrk, T.C.; Sinicrope, F.A. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Ann. Oncol. 2020, 31, 487–494. [Google Scholar] [CrossRef] [PubMed]
- Saberzadeh-Ardestani, B.; Foster, N.R.; Lee, H.E.; Shi, Q.; Alberts, S.R.; Smyrk, T.C.; Sinicrope, F.A. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]. Ann. Oncol. 2022, 33, 1159–1167. [Google Scholar] [CrossRef] [PubMed]
- Baran, B.; Mert Ozupek, N.; Yerli Tetik, N.; Acar, E.; Bekcioglu, O.; Baskin, Y. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterol. Res. 2018, 11, 264–273. [Google Scholar] [CrossRef]
- De Cuyper, A.; Van Den Eynde, M.; Machiels, J.-P. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. Clin. Color. Cancer 2020, 19, 65–72. [Google Scholar] [CrossRef] [PubMed]
- Boeckx, N.; Koukakis, R.; Op De Beeck, K.; Rolfo, C.; Van Camp, G.; Siena, S.; Tabernero, J.; Douillard, J.-Y.; André, T.; Peeters, M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies. Ann. Oncol. 2017, 28, 1862–1868. [Google Scholar] [CrossRef] [PubMed]
- Bustamante-Lopez, L.A.; Nahas, S.C.; Nahas, C.S.R.; Pinto, R.A.; Marques, C.F.S.; Cecconello, I. IS THERE A DIFFERENCE BETWEEN RIGHT- VERSUS LEFT-SIDED COLON CANCERS? DOES SIDE MAKE ANY DIFFERENCE IN LONG-TERM FOLLOW-UP? ABCD Arq. Bras. Cir. Dig. 2019, 32, e1479. [Google Scholar] [CrossRef]
- Venderbosch, S.; Nagtegaal, I.D.; Maughan, T.S.; Smith, C.G.; Cheadle, J.P.; Fisher, D.; Kaplan, R.; Quirke, P.; Seymour, M.T.; Richman, S.D.; et al. Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clin. Cancer Res. 2014, 20, 5322–5330. [Google Scholar] [CrossRef] [PubMed]
- Wu, S.; Ma, C.; Li, W. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn. Pathol. 2015, 10, 144. [Google Scholar] [CrossRef]
- Yalikong, A.; Li, X.-Q.; Zhou, P.-H.; Qi, Z.-P.; Li, B.; Cai, S.-L.; Zhong, Y.-S. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. IJN 2021, 16, 2323–2335. [Google Scholar] [CrossRef]
- Raghav, K.; Loree, J.M.; Morris, J.S.; Overman, M.J.; Yu, R.; Meric-Bernstam, F.; Menter, D.; Korphaisarn, K.; Kee, B.; Muranyi, A.; et al. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis. Oncol. 2019, 3, 1–13. [Google Scholar] [CrossRef]
- Hainsworth, J.D.; Meric-Bernstam, F.; Swanton, C.; Hurwitz, H.; Spigel, D.R.; Sweeney, C.; Burris, H.A.; Bose, R.; Yoo, B.; Stein, A.; et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. JCO 2018, 36, 536–542. [Google Scholar] [CrossRef] [PubMed]
- Ingold Heppner, B.; Behrens, H.-M.; Balschun, K.; Haag, J.; Krüger, S.; Becker, T.; Röcken, C. HER2/neu testing in primary colorectal carcinoma. Br. J. Cancer 2014, 111, 1977–1984. [Google Scholar] [CrossRef] [PubMed]
- Yagisawa, M.; Sawada, K.; Nakamura, Y.; Fujii, S.; Yuki, S.; Komatsu, Y.; Yoshino, T.; Sakamoto, N.; Taniguchi, H. Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. Clin. Color. Cancer 2021, 20, 113–120.e1. [Google Scholar] [CrossRef] [PubMed]
- Puccini, A.; Lenz, H.-J.; Marshall, J.L.; Arguello, D.; Raghavan, D.; Korn, W.M.; Weinberg, B.A.; Poorman, K.; Heeke, A.L.; Philip, P.A.; et al. Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist 2019, 24, 319–326. [Google Scholar] [CrossRef] [PubMed]
- Park, D.I.; Kang, M.S.; Oh, S.J.; Kim, H.J.; Cho, Y.K.; Sohn, C.I.; Jeon, W.K.; Kim, B.I.; Han, W.K.; Kim, H.; et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int. J. Color. Dis. 2007, 22, 491. [Google Scholar] [CrossRef] [PubMed]
- Siena, S.; Sartore-Bianchi, A.; Marsoni, S.; Hurwitz, H.I.; McCall, S.J.; Penault-Llorca, F.; Srock, S.; Bardelli, A.; Trusolino, L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann. Oncol. 2018, 29, 1108–1119. [Google Scholar] [CrossRef] [PubMed]
- Parikh, A.; Atreya, C.; Korn, W.M.; Venook, A.P. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. J. Natl. Compr. Canc Netw. 2017, 15, 3–8. [Google Scholar] [CrossRef]
Gender | Values | LCC n * = 75/26/101 | RCC n ** = 49/31/80 | Total n *** = 124/57/181 | p Value 1 |
---|---|---|---|---|---|
Male | average (SD) | 62.9 (9.1) | 62.6 (9.8) | 62.8 (9.3) | 0.833 |
min–max | 30–75 | 36–76 | 30–76 | ||
Female | average (SD) | 57.6 (10.4) | 59.5 (12.8) | 58.6 (11.7) | 0.553 |
min–max | 37–79 | 21–76 | 21–79 | ||
All | average (SD) | 61.6 (9.6) | 61.4 (11.1) | 61.5 (10.3) | 0.902 |
min–max | 30–79 | 21–76 | 21–79 | ||
p value 1 | 0.015 | 0.227 | 0.011 |
Parameters | Values | LCC n = 101 | RCC n = 81 | p Value 1 |
---|---|---|---|---|
Pathohistological type of tumor | Mucinous | 3 (3.0%) | 15 (18.8%) | 0.001 |
NOS | 97 (96.0%) | 63 (78.8%) | ||
Singnet ring cell | 1 (1.0%) | 2 (2.5%) | ||
Differentiation | Good | 15 (14.9%) | 7 (7.8%) | 0.031 |
Moderate | 75 (74.3%) | 53 (66.2%) | ||
Poor | 11 (10.9%) | 20 (25.0%) | ||
Resection margins | R0 | 85 (84.2%) | 72 (90.0%) | 0.442 |
R1 | 6 (5.9%) | 4 (5.0%) | ||
Palliative surgery | 10 (9.9%) | 4 (5.0%) | ||
Tumor infiltration lymphocyte | Dense | 19 (18.8%) | 11 (13.8%) | 0.176 |
Poor | 23 (22.8%) | 28 (35.0%) | ||
Moderate | 59 (58.4%) | 41 (51.2%) | ||
Stage at diagnosis | II | 13 (12.9%) | 15 (18.8%) | 0.283 |
III | 39 (38.6%) | 35 (43.8%) | ||
IV | 49 (48.5%) | 30 (37.5%) | ||
No. of examined LN | Average (SD) | 14.4 (8.7) | 18.2 (9.6) | 0.003 |
Min–max | 0–40 | 0–50 | ||
No. of positive LN | Average (SD) | 4.19 (4.7) | 5.29 (5.8) | 0.414 |
Min–max | 0–25 | 0–25 | ||
No. of metastatic sites | Average (SD) | 1.37 (0.66) | 1.60 (0.79) | 0.035 |
Min–max | 1–5 | 1–4 | ||
Lymph node involvement | Present | 6 (5.9%) | 3 (3.8%) | 0.742 |
Lymphovascular invasion | Present | 76 (75.2%) | 55 (68.8%) | 0.332 |
Perineural invasion | Present | 64 (63.4%) | 50 (62.5%) | 0.905 |
Ileus | Present | 28 (27.7%) | 24 (30.0%) | 0.737 |
Metastatic sites | Liver | 73.9% | 72.5% | 0.908 |
Lung | 20.8% | 22.5% | 0.781 | |
LN of abdomen | 12.9% | 25.0% | 0.036 | |
Local recurrence | 9.9% | 6.2% | 0.376 | |
LN of pelvis | 5.0% | 11.2% | 0.115 | |
Carcinosis of peritoneum | 3.0% | 8.9% | 0.091 | |
LN of thorax | 1.0% | 7.5% | 0.062 | |
Ovary | 3.0% | 1.2% | 0.785 | |
Bones | 2.0% | 1.2% | 1.000 | |
Adrenal gland | 2.0% | 1.2% | 1.000 | |
Brain | 1.0% | 1.2% | 1.000 | |
Urinary bladder | 2.0% | 0.0% | 0.582 | |
Prostate | 1.0% | 0.0% | 1.000 | |
Pancreas | 1.0% | 0.0% | 1.000 |
Line of Therapy | LCC n = 101 | RCC n = 80 | Total n = 181 | p Value 1 |
---|---|---|---|---|
II | 3 (3.0%) | 5 (6.2%) | 8 (4.4%) | 0.162 |
III | 88 (87.1%) | 72 (90.0%) | 160 (88.4%) | |
IV | 10 (9.9%) | 3 (3.8%) | 13 (7.2%) |
Predictors in CRC | B | SE | p 1 | Exp(B) | 95% CI |
---|---|---|---|---|---|
Mucinous adenocarcinoma | 0.990 | 0.269 | <0.001 | 2.69 | 1.59–4.56 |
Right localization of primary tumor | 0.375 | 0.164 | 0.022 | 1.46 | 1.06–2.01 |
Perineural invasion | 0.355 | 0.167 | 0.034 | 1.43 | 1.03–1.98 |
Resection margins end palliative surgery | 0.518 | 0.263 | 0.049 | 1.68 | 1.02–2.81 |
Predictors in LCC | B | SE | p 1 | Exp(B) | 95% CI |
---|---|---|---|---|---|
Perineural invasion | 0.468 | 0.225 | 0.038 | 1.60 | 1.03–2.48 |
Predictors in RCC | B | SE | p 1 | Exp(B) | 95% CI |
Mucinous adenocarcinoma | 1.136 | 0.304 | <0.001 | 3.12 | 1.72–5.66 |
Predictors in CRC | B | SE | p 1 | Exp(B) | 95% CI |
---|---|---|---|---|---|
Mucinous adenocarcinoma | 0.927 | 0.270 | 0.001 | 2.53 | 1.49–4.29 |
Right localization of primary tumor | 0.471 | 0.165 | 0.004 | 1.60 | 1.16–2.21 |
Parameters | Characteristics | Not Responded n = 79 | Good Response n = 102 | p Value 1 |
---|---|---|---|---|
LPT | Right | 49 (61.2%) | 31 (30.8%) | <0.001 |
Left | 30 (29.7%) | 71 (70.3%) | ||
Pathohistological type of tumor | NOS, SRCC | 64 (39.3%) | 99 (60.7%) | 0.001 |
Mucinous | 15 (83.3%) | 3 (16.7%) | ||
Differentiation | Good | 7 (31.8%) | 15 (68.2%) | 0.233 |
Moderate, poor | 72 (45.3%) | 87 (54.7%) | ||
Stage of disease | II | 11 (39.3%) | 17 (60.7%) | 0.613 |
III, IV | 68 (44.4%) | 85 (55.6%) | ||
No. examined LN | <11 | 18 (34.6%) | 34 (65.4%) | 0.120 |
>12 | 61 (47.3%) | 68 (52.7%) | ||
Involved LN | No | 16 (36.4%) | 28 (63.6%) | 0.263 |
Yes | 63 (46.0%) | 74 (54.0%) | ||
Resection margins and palliative surgery | R0 | 69 (43.9%) | 88 (56.1%) | 0.541 |
R1, R2 | 10 (41.7%) | 14 (58.3%) | ||
LVI | No | 20 (40.0%) | 30 (60.0%) | 0.188 |
Yes | 59 (45.0%) | 72 (55.0%) | ||
PNI | No | 25 (37.3%) | 42 (62.7%) | 0.834 |
Yes | 54 (47.4%) | 60 (52.6%) | ||
TIL | Poor, moderate | 25 (49.0%) | 26 (51.0%) | 0.361 |
Dense | 54 (41.5%) | 76 (58.5%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Radić, J.; Nikolić, I.; Kolarov-Bjelobrk, I.; Vasiljević, T.; Djurić, A.; Vidović, V.; Kožik, B. Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia. J. Pers. Med. 2024, 14, 879. https://doi.org/10.3390/jpm14080879
Radić J, Nikolić I, Kolarov-Bjelobrk I, Vasiljević T, Djurić A, Vidović V, Kožik B. Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia. Journal of Personalized Medicine. 2024; 14(8):879. https://doi.org/10.3390/jpm14080879
Chicago/Turabian StyleRadić, Jelena, Ivan Nikolić, Ivana Kolarov-Bjelobrk, Tijana Vasiljević, Aleksandar Djurić, Vladimir Vidović, and Bojana Kožik. 2024. "Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia" Journal of Personalized Medicine 14, no. 8: 879. https://doi.org/10.3390/jpm14080879
APA StyleRadić, J., Nikolić, I., Kolarov-Bjelobrk, I., Vasiljević, T., Djurić, A., Vidović, V., & Kožik, B. (2024). Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia. Journal of Personalized Medicine, 14(8), 879. https://doi.org/10.3390/jpm14080879